About Immusoft
Immusoft is a company based in Seattle (United States) founded in 2009 by Matthew Scholz.. Immusoft has raised $44.13 million across 15 funding rounds from investors including ARE, State of California and NIH. Immusoft has completed 1 acquisition, including Discovery Genomics. Immusoft offers products and services including Immune System Programming (ISP™) and B Cell Biofactory Technology. Immusoft operates in a competitive market with competitors including Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
- Headquarter Seattle, United States
- Founders Matthew Scholz
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Immusoft Corporation
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$44.13 M (USD)
in 15 rounds
-
Latest Funding Round
$4.58 M (USD), Series B
May 28, 2024
-
Investors
ARE
& 17 more
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Immusoft
Immusoft offers a comprehensive portfolio of products and services, including Immune System Programming (ISP™) and B Cell Biofactory Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Engineers B cells to produce therapeutic proteins for genetic diseases.
Programs cells for long-term protein secretion in patients.
Unlock access to complete
Unlock access to complete
Funding Insights of Immusoft
Immusoft has successfully raised a total of $44.13M across 15 strategic funding rounds. The most recent funding activity was a Series B round of $4.58 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 15
- Last Round Series B — $4.6M
- First Round First Round
- Investors Count 18
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2024 | Amount | Series B - Immusoft | Valuation |
investors |
|
| Jan, 2023 | Amount | Grant - Immusoft | Valuation |
investors |
|
| Nov, 2021 | Amount | Grant - Immusoft | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Immusoft
Immusoft has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, State of California and NIH. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Biovision Ventures is focused on investing in life sciences and healthcare innovations.
|
Founded Year | Domain | Location | |
|
RV Invest is engaged in funding biotech innovations.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Immusoft
Immusoft has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Discovery Genomics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Gene therapies for blood diseases
|
2000 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Immusoft
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Immusoft Comparisons
Competitors of Immusoft
Immusoft operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of precision therapeutics for dry AMD and rare genetic diseases
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| domain | founded_year | HQ Location |
B cell therapies are developed for oncology and rare diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Immusoft
Frequently Asked Questions about Immusoft
When was Immusoft founded?
Immusoft was founded in 2009 and raised its 1st funding round 3 years after it was founded.
Where is Immusoft located?
Immusoft is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Is Immusoft a funded company?
Immusoft is a funded company, having raised a total of $44.13M across 15 funding rounds to date. The company's 1st funding round was a Grant of $4M, raised on Apr 21, 2012.
What does Immusoft do?
Immusoft was founded in 2009 in Seattle, United States, within the biotechnology sector focused on cell therapies. Patient B cells are collected, engineered to generate personalized proteins, expanded in number, and reinfused to act as ongoing production sites. This method supports sustained in vivo protein expression for medical applications, with operations centered on developing these programmable cellular systems.
Who are the top competitors of Immusoft?
Immusoft's top competitors include Alnylam, BioMarin Pharmaceutical and Be Bio.
What products or services does Immusoft offer?
Immusoft offers Immune System Programming (ISP™) and B Cell Biofactory Technology.
How many acquisitions has Immusoft made?
Immusoft has made 1 acquisition, including Discovery Genomics.
Who are Immusoft's investors?
Immusoft has 18 investors. Key investors include ARE, State of California, NIH, HHS, and NYBC Ventures.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.